title: Effects of a hydroxylated metabolite of the beta-andrenoreceptor antagonist, carvedilol, on post-ischaemic splachnic tissue injury.
abstract: 1 Reactive oxygen species have been demonstrated to play a critical role in post-ischaemic tissue injury. The present experiment was designed to evaluate the effects of SB 211475, a hydroxylated metabolite of the new beta-adrenoceptor antagonist, carvedilol, on rat splanchnic ischaemia (SI, 60 min) and reperfusion(R)-induced shock and tissue injury. 2 Administration of SB 211475 two min before R attenuated SI/R injury in a dose-dependent manner. At doses of 0.5 mg kg(-1) and 1.0 mg kg(-1), SB 211475 exerted significant anti-shock and endothelial protective effects, characterized by prolonged survival times, increased survival rates, attenuated increases in tissue myeloperoxidase activity and haematocrits, and preserved endothelium-dependent vasorelaxation. 3 Administration of 1 mg kg(-1) carvedilol attenuated shock-induced tissue injury and endothelial dysfunction. However, administration of 0.5 mg kg(-1) carvedilol had no protective effects on post-ischaemic tissue injury. 4 Previous studies have shown that SB 211475 has virtually no beta-blocking activity but possesses more potent antioxidant activity than carvedilol. In the present study, SB 211475 exerted more potent protective effects than the parent compound, suggesting that this metabolite of carvedilol is superior to carvedilol with regard to its protection against post-ischaemia tissue injury.
authors.affiliation: Division of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19107-5004, USA.
authors.forename: T A
authors.initials: TA
authors.lastname: Christopher
authors.forename: B L
authors.initials: BL
authors.lastname: Lopez
authors.forename: X L
authors.initials: XL
authors.lastname: Ma
authors.forename: G Z
authors.initials: GZ
authors.lastname: Feuerstein
authors.forename: R R
authors.initials: RR
authors.lastname: Ruffolo
authors.forename: T L
authors.initials: TL
authors.lastname: Yue
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077261:Carvedilol; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D066298:In Vitro Techniques; D007511:Ischemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D017538:Mesenteric Artery, Superior / Q000187:drug effects* / Q000473:pathology; D009126:Muscle Relaxation / Q000187:drug effects / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000098:blood supply* / Q000187:drug effects / Q000473:pathology; D009195:Peroxidase / Q000378:metabolism; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000517:prevention & control*
chemical_list: D000319:Adrenergic beta-Antagonists; D000975:Antioxidants; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; C086740:SB 211475; D009195:Peroxidase